Terms: = Kidney tumors AND PPARG, PPARG1, 5468, ENSG00000132170, PPARG2, NR1C3, HUMPPARG AND Treatment
5 results:
1.
Situ Y; Zhang J; Liao W; Liang Q; Lu L; Xu Q; Chen J; Lu X; Cui Y; Shao Z; Deng L
Front Biosci (Landmark Ed); 2023 Sep; 28(9):196. PubMed ID: 37796681
[TBL] [Abstract] [Full Text] [Related]
2. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
[No Abstract] [Full Text] [Related]
3.
Wu Y; Song T; Liu M; He Q; Chen L; Liu Y; Ni D; Liu J; Hu Y; Gu Y; Li Q; Zhou Q; Xie Y
DNA Cell Biol; 2019 Jul; 38(7):700-707. PubMed ID: 31090452
[TBL] [Abstract] [Full Text] [Related]
4. Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
Rochel N; Krucker C; Coutos-Thévenot L; Osz J; Zhang R; Guyon E; Zita W; Vanthong S; Hernandez OA; Bourguet M; Badawy KA; Dufour F; Peluso-Iltis C; Heckler-Beji S; Dejaegere A; Kamoun A; de Reyniès A; Neuzillet Y; Rebouissou S; Béraud C; Lang H; Massfelder T; Allory Y; Cianférani S; Stote RH; Radvanyi F; Bernard-Pierrot I
Nat Commun; 2019 Jan; 10(1):253. PubMed ID: 30651555
[TBL] [Abstract] [Full Text] [Related]
5. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma.
Zagoria RJ; Pettus JA; Rogers M; Werle DM; Childs D; Leyendecker JR
Urology; 2011 Jun; 77(6):1393-7. PubMed ID: 21492910
[TBL] [Abstract] [Full Text] [Related]
